397 related articles for article (PubMed ID: 35546184)
1. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.
Ingels A; Campi R; Capitanio U; Amparore D; Bertolo R; Carbonara U; Erdem S; Kara Ö; Klatte T; Kriegmair MC; Marchioni M; Mir MC; Ouzaïd I; Pavan N; Pecoraro A; Roussel E; de la Taille A
Nat Rev Urol; 2022 Jul; 19(7):391-418. PubMed ID: 35546184
[TBL] [Abstract][Full Text] [Related]
2. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
[TBL] [Abstract][Full Text] [Related]
3. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
[TBL] [Abstract][Full Text] [Related]
4. Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC.
Das A; Shapiro DD; Craig JK; Abel EJ
Nat Rev Urol; 2023 Nov; 20(11):654-668. PubMed ID: 37400492
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review.
Ghoreifi A; Vaishampayan U; Yin M; Psutka SP; Djaladat H
JAMA Oncol; 2024 Feb; 10(2):240-248. PubMed ID: 38095885
[TBL] [Abstract][Full Text] [Related]
6. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
[TBL] [Abstract][Full Text] [Related]
7. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
[TBL] [Abstract][Full Text] [Related]
8. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
Hsiang WR; Kenney PA; Leapman MS
Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
[TBL] [Abstract][Full Text] [Related]
9. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
Reed JP; Posadas EM; Figlin RA
Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive nephrectomy: does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything?
Grant M; Szabados B; Kuusk T; Powles T; Bex A
Curr Opin Urol; 2020 Jan; 30(1):36-40. PubMed ID: 31789991
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.
Fitzgerald KN; Motzer RJ; Lee CH
Nat Rev Urol; 2023 Mar; 20(3):179-193. PubMed ID: 36369389
[TBL] [Abstract][Full Text] [Related]
12. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
13. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
14. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
De Gobbi A; Biasoni D; Catanzaro M; Nicolai N; Piva L; Stagni S; Torelli T; Procopio G; Verzoni E; Grassi P; Colecchia M; Paolini B; Spreafico C; Marchianò A; Salvioni R
Tumori; 2018 Oct; 104(5):388-393. PubMed ID: 28085177
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.
Abel EJ; Wood CG
Nat Rev Urol; 2009 Jul; 6(7):375-83. PubMed ID: 19528960
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
Chery LJ; Karam JA; Wood CG
Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
18. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
Karam JA; Wood CG
Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors.
Biles MJ; Patel HD; Allaf ME
Urol Clin North Am; 2020 Aug; 47(3):359-370. PubMed ID: 32600537
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Biswas S; Kelly J; Eisen T
Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
